ClinicalTrials.gg
RecruitingNCT03315468RIC-MelUpdated Jul 22, 2025

French Clinical Datbase of Melanoma Patients (RIC-Mel)

An observational study in Melanoma (Skin), sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Nantes University Hospital · Observational

From the registry’s dates

  • Started Mar 2012; still recruiting 14 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Melanoma by Nantes University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Melanoma · Nantes University Hospital.

Started
2012
with 1 other
Observational
5 of 13
3 open now
Registered
9th of 13
by date

Among the 13 studies in Melanoma by Nantes University Hospital, this one is one of 2 that started in 2012, is one of 5 observational ones, and was the 9th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 13 studies in Melanoma by Nantes University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Melanoma by Nantes University Hospital, or all of them as a file.
02

Study summary

With a high incidence, low survival rates and limiter availability of effective treatment, melanoma is one of the research priorities for health authorities. Optimizing the development of both academic and private research requires the availability information on the features of patients.

To meet this need, the French Multidisciplinary Melanoma Group (GMFMel) in collaboration with INCa (French National Cancer Institute), the CeNGEPS (National Centre for Healthcare Products Trial Management) and the CIC-BT0503 from Nantes University Hospital (Biotherapy Clinical Centre of Investigation) has set up in April 2011 a Clinical Investigation Network for melanoma, called the CeNGEPS-GMFMel network. Nowadays, the network is named :

RIC-Mel : network for Research and Clinical Investigation on Melanoma. Aims of the network are to promote translational and epidemiological projects as well as to optimize the achievements of clinical trials.

To achieve these goals, a database was launched in 2012 that gives a permanently updates mapping of melanoma treated in France with the key information needed for any research projects.

Read the detailed description

The RIC-Mel network federate clinicians researchers working in clinical and translational research for melanoma and carrying out patients inclusions in the clinical trials. These clinicians are working on clinical cancerology and dermatology sites located throughout the French national territory. Nowadays, the RIC-Mel network consists of 49 centers: 43 public dermatology centers (Hospital centers) and 6 private centers (Cancer centers). The RIC-Mel network is coordinated by Pr B. DRENO (Nantes University Hospital) and Pr C. LEBBE (Saint-Louis Hospital, AP-HP, Paris).

The RIC-Mel database is referred as one of the privileged access to any research program on melanoma by the Cancerology Group of the French Society of Dermatology.

The RIC-Mel database has been approved by French health authorities, both ethically and for confidentiality of data (CCTIRS and CNIL). The database is available on the internet at any given moment thanks to a secure connection. All data are treated confidentially. The active file of patients with melanoma from each participating center is available in the database. All patients agreed to participate may be included in the database, regardless of their stage. Clinical data are collected thanks two forms :

  • Part I key clinical data for any clinical trial Primary tumour (date of surgery, breslow…), lymph node removal (date, number of invaded lymph node…), AJCC stage, Mutation status, melanoma antigens, melanoma treatments (type, dates) and death.
  • Part II: additional data for epidemiological and translational research Family history of melanoma, metastases (type, date of diagnosis…), HLA A and B type, additional information on treatments (dose, overall response, grade 3 or 4 side effects with the type, action on treatment and outcome).

In September 2017, more than 20,000 patients with melanoma had been included in the RIC-Mel database, with the following distribution: around 75% of primary stages (0 to II) and 25 % of metastatic stages (III and IV).

03

Conditions studied

  • Melanoma (Skin)

Browse trials for

Keywords

  • melanoma
  • database
  • cohort
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with melanoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with melanoma, of any stage,
  • Patient agreed to participate.

Exclusion criteria

Exclusion Criteria:

  • Individuals under court protection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Overall survival of melanoma patients included in the RIC-Mel database

    Overall survival if defined as the time between the primary melanoma tumour removal and the death or the date of data extraction from the RIC-Mel database for alive patients.

    Time frame: 5 years

Secondary outcomes

  1. Percentage of melanoma patients included in the RIC-Mel database categorized by genders

    Distribution of females and males

    Time frame: through study completion, an average of 5 years

  2. Percentage of melanoma patients included in the RIC-Mel database categorized by histological subtypes

    Histological subtypes of primary melanoma were categorized as Superficial spreading melanoma, nodular, lentigo maligna melanoma, acral lentiginous melanoma, mucosal, ocular, unknown primary melanoma, and others subtypes. This information is collected from medical records of each patient

    Time frame: Day 1

  3. Percentage of melanoma patients included in the RIC-Mel database categorized by breslow thickness

    Breslow thickness is defined as the total vertical height of the melanoma, from the very top (called the granular layer) to the area of deepest penetration in the skin. Breslow thickness is the one of the important prognostic factor and it is commonly reported that the higher the Breslow thickness, the worse the prognosis. This information is collected from medical records of each patient. The classifications were lesser than or equal to (≤) 1.0 millimeters (mm), 1.01 - 2.0 mm, 2.01 - 4.0 mm, greater than (\>) 4.0 mm and Unknown.

    Time frame: day 1

  4. Percentage of melanoma patients included in the RIC-Mel database categorized by ulceration

    Ulceration is defined as an erosion of the first primary tumour, associated with the death of cancer cells in the tumour center. Ulceration is, with breslow thickness, another important prognostic factor. Ulceration is associated with a worth prognostic. This information is collected from medical records of each patient. The classifications were Yes, No and Unknown.

    Time frame: day 1

  5. Percentage of melanoma patients included in the RIC-Mel database categorized by Melanoma stage

    Melanoma stages were categorized (according to American Joint Committee on Cancer \[AJCC\]) as 0 (in situ melanoma), I and II (only primary tumour without any metastasis), III (locally advanced stage of melanoma regarding location of the primary tumour with lymph nodes and/or cutaneous metastasis), IV (advanced stage of melanoma with lymph nodes and/or cutaneous distant metastasis or any other type of metastasis). This information is collected from medical records of each patient

    Time frame: day 1

  6. Percentage of Participants With Mutation Status

    Presence or absence of mutations in the BRAF, NRAS and ckit oncogenes were determined thanks to each's centres practices. This information is collected from medical records of each patient.The classifications for each gene were Yes (mutated), No (non-mutated = wild type) and Unknown (no research).

    Time frame: Day 1

  7. Percentage of treatment types among melanoma stage

    Possible treatments types: Radiotherapy, Immunotherapy, Targeted therapies, Chemotherapy, Experimental treatment, Interferon, Others (for surgical approaches). All treatments reported in the RIC-Mel database only concerned those provided in the care of melanoma. This information is collected from medical records of each patient.

    Time frame: through study completion, an average of 5 years

  8. Progression-free survival of melanoma patients included in the RIC-Mel database

    Progression-free survival if defined as the time between the primary melanoma tumour removal and the appearance of the first metastasis.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2012 (actual). Primary completion is estimated for Mar 2030, 216 months after the start.

Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 216 months is above that.

Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Oct 20, 2017
StartActual
Mar 1, 2012
Primary completionEst.
Mar 1, 2030
CompletionEst.
Mar 1, 2030
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03315468
Responsible party
Sponsor
First posted
Oct 20, 2017
Start date
Mar 1, 2012
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Jul 22, 2025

Study contacts

Gaëlle Quereux, PU-PH
Contact
gaelle.quereux@chu-nantes.fr
Amir Khammari
Contact
amir.khammari@chu-nantes.fr
Gaëlle Quereux, PU-PH
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion